search
Back to results

eXciteOSA for Treatment of Mild Obstructive Sleep Apnea (OREM)

Primary Purpose

Sleep Apnea, Obstructive

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
eXciteOSA
Sponsored by
Signifier Medical Technologies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Apnea, Obstructive

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged >=18 years;
  • Diagnosed with mild OSA;
  • Smartphone or tablet capable of running the eXciteOSA app;
  • Fluent in written and spoken English (all sites) or Spanish (one site only).

Exclusion Criteria:

  • BMI >=35 kg/m2;
  • Implanted medical device;
  • Dental braces and/or intraoral metal jewelry;
  • Any condition impacting the tissue of the oral cavity, including but not limited to ulceration or periodontitis;
  • Symptomatic nasal pathology such as septal deviation, nasal polyposis, or chronic rhinosinusitis;
  • Tonsillar hypertrophy (tonsil size grade 3 or greater);
  • Clinically significant facial or oropharyngeal abnormalities such as class 2 malocclusion;
  • Prior oropharyngeal surgery for sleep-disordered breathing;
  • At-home use of a mandibular advancement device or PAP for sleep-disordered breathing within the previous four weeks;
  • Use of any overnight therapy that cannot be withdrawn during study enrollment;
  • Diagnosed with any sleep disorder other than OSA;
  • Chronic use of central nervous system depressants;
  • Driver in a sleepiness-related vehicular accident or near-miss within the two years prior to enrolment (self-report);
  • Employed as a commercial driver, pilot, or other occupation that may be impacted by hypersomnolence;
  • Considered by the PI to be at risk of an AE resulting from hypersomnolence;
  • Any periods of non-connectivity (wifi or cellular data) exceeding 48 hours planned to take place, or likely to take place, during enrollment;
  • Current or planned pregnancy;
  • Member of a vulnerable population, including but not limited to prisoners and those lacking consent capacity;
  • Clinically-significant burden of comorbidities, and/or any other limitation or condition that may impact the patient's ability to complete the study protocol and use the device per the Instructions for Use (PI discretion);
  • Employee and/or residing household member who is an employee of a company that produces or distributes products designed to diagnose, treat, and/or monitor sleep or sleep-disordered breathing (including the Sponsor).

Sites / Locations

  • Sleep Disorders Center of Alabama
  • Delta Waves
  • Florida Lung & Sleep Associates
  • Pulmonary and Critical Care Associates of Baltimore
  • Clayton Sleep Institute
  • Ohio Sleep Medicine Institute
  • Bogan Sleep Consultants

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Therapy

No Therapy

Arm Description

Neuromuscular electrical stimulation

Under the care of the referring physician, with no therapy applied

Outcomes

Primary Outcome Measures

Respiratory event index
The difference in the delta-REI (baseline to follow-up) between arms

Secondary Outcome Measures

Full Information

First Posted
December 20, 2021
Last Updated
December 1, 2022
Sponsor
Signifier Medical Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT05183009
Brief Title
eXciteOSA for Treatment of Mild Obstructive Sleep Apnea
Acronym
OREM
Official Title
An Open-label Randomized Controlled Trial Assessing the Efficacy of Intraoral Neuromuscular Electrical Stimulation for Treatment of Mild Obstructive Sleep Apnea: The OREM Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 17, 2022 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Signifier Medical Technologies

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to assess the efficacy of the eXciteOSA device amongst a sample of patients with mild OSA. The study is a multi-center, prospective, open-label, randomized, parallel-arm trial of eXciteOSA versus no-therapy for six weeks. Up to 200 participants will be enrolled, in order to randomized n=102.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea, Obstructive

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
102 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Therapy
Arm Type
Experimental
Arm Description
Neuromuscular electrical stimulation
Arm Title
No Therapy
Arm Type
No Intervention
Arm Description
Under the care of the referring physician, with no therapy applied
Intervention Type
Device
Intervention Name(s)
eXciteOSA
Intervention Description
eXciteOSA
Primary Outcome Measure Information:
Title
Respiratory event index
Description
The difference in the delta-REI (baseline to follow-up) between arms
Time Frame
Six weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged >=18 years; Diagnosed with mild OSA; Smartphone or tablet capable of running the eXciteOSA app; Fluent in written and spoken English (all sites) or Spanish (one site only). Exclusion Criteria: BMI >=35 kg/m2; Implanted medical device; Dental braces and/or intraoral metal jewelry; Any condition impacting the tissue of the oral cavity, including but not limited to ulceration or periodontitis; Symptomatic nasal pathology such as septal deviation, nasal polyposis, or chronic rhinosinusitis; Tonsillar hypertrophy (tonsil size grade 3 or greater); Clinically significant facial or oropharyngeal abnormalities such as class 2 malocclusion; Prior oropharyngeal surgery for sleep-disordered breathing; At-home use of a mandibular advancement device or PAP for sleep-disordered breathing within the previous four weeks; Use of any overnight therapy that cannot be withdrawn during study enrollment; Diagnosed with any sleep disorder other than OSA; Chronic use of central nervous system depressants; Driver in a sleepiness-related vehicular accident or near-miss within the two years prior to enrolment (self-report); Employed as a commercial driver, pilot, or other occupation that may be impacted by hypersomnolence; Considered by the PI to be at risk of an AE resulting from hypersomnolence; Any periods of non-connectivity (wifi or cellular data) exceeding 48 hours planned to take place, or likely to take place, during enrollment; Current or planned pregnancy; Member of a vulnerable population, including but not limited to prisoners and those lacking consent capacity; Clinically-significant burden of comorbidities, and/or any other limitation or condition that may impact the patient's ability to complete the study protocol and use the device per the Instructions for Use (PI discretion); Employee and/or residing household member who is an employee of a company that produces or distributes products designed to diagnose, treat, and/or monitor sleep or sleep-disordered breathing (including the Sponsor).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yasser Zayni
Organizational Affiliation
Signifier Medical Technologies
Official's Role
Study Director
Facility Information:
Facility Name
Sleep Disorders Center of Alabama
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35213
Country
United States
Facility Name
Delta Waves
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80918
Country
United States
Facility Name
Florida Lung & Sleep Associates
City
Lehigh Acres
State/Province
Florida
ZIP/Postal Code
33971
Country
United States
Facility Name
Pulmonary and Critical Care Associates of Baltimore
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21286
Country
United States
Facility Name
Clayton Sleep Institute
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63143
Country
United States
Facility Name
Ohio Sleep Medicine Institute
City
Dublin
State/Province
Ohio
ZIP/Postal Code
43017
Country
United States
Facility Name
Bogan Sleep Consultants
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29201
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

eXciteOSA for Treatment of Mild Obstructive Sleep Apnea

We'll reach out to this number within 24 hrs